Evidence map›Paper›PMID 28617226›Full record

ArticleBMC bioinformatics2017

Contextualization of drug-mediator relations using evidence networks.

Hai Joey Tran, Gil Speyer, Jeff Kiefer, Seungchan Kim

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hai Joey TranIntegrated Cancer Genomics Division, The Translational Genomics Research Institute, Phoenix, AZ, 85004, USA.
Gil SpeyerIntegrated Cancer Genomics Division, The Translational Genomics Research Institute, Phoenix, AZ, 85004, USA.
Jeff KieferIntegrated Cancer Genomics Division, The Translational Genomics Research Institute, Phoenix, AZ, 85004, USA.
Seungchan KimIntegrated Cancer Genomics Division, The Translational Genomics Research Institute, Phoenix, AZ, 85004, USA. sekim@pvamu.edu.
Translational Genomics Research Institute · USPrairie View A&M University · US

Funding

Systematic Development of Novel, Druggable Cancer TargetsU01CA168397 · NCI · TRANSLATIONAL GENOMICS RESEARCH INST · PI BERENS, MICHAEL E. · 2012 to 2016
$4.1M
NCI NIH HHS U01 CA168397
6 · The paper itself

Abstract

backgroundGenomic analysis of drug response can provide unique insights into therapies that can be used to match the "right drug to the right patient." However, the process of discovering such therapeutic insights using genomic data is not straightforward and represents an area of active investigation. EDDY (Evaluation of Differential DependencY), a statistical test to detect differential statistical dependencies, is one method that leverages genomic data to identify differential genetic dependencies. EDDY has been used in conjunction with the Cancer Therapeutics Response Portal (CTRP), a dataset with drug-response measurements for more than 400 small molecules, and RNAseq data of cell lines in the Cancer Cell Line Encyclopedia (CCLE) to find potential drug-mediator pairs. Mediators were identified as genes that showed significant change in genetic statistical dependencies within annotated pathways between drug sensitive and drug non-sensitive cell lines, and the results are presented as a public web-portal (EDDY-CTRP). However, the interpretability of drug-mediator pairs currently hinders further exploration of these potentially valuable results.

methodsIn this study, we address this challenge by constructing evidence networks built with protein and drug interactions from the STITCH and STRING interaction databases. STITCH and STRING are sister databases that catalog known and predicted drug-protein interactions and protein-protein interactions, respectively. Using these two databases, we have developed a method to construct evidence networks to "explain" the relation between a drug and a mediator. 

resultsWe applied this approach to drug-mediator relations discovered in EDDY-CTRP analysis and identified evidence networks for ~70% of drug-mediator pairs where most mediators were not known direct targets for the drug. Constructed evidence networks enable researchers to contextualize the drug-mediator pair with current research and knowledge. Using evidence networks, we were able to improve the interpretability of the EDDY-CTRP results by linking the drugs and mediators with genes associated with both the drug and the mediator.

conclusionWe anticipate that these evidence networks will help inform EDDY-CTRP results and enhance the generation of important insights to drug sensitivity that will lead to improved precision medicine applications.

Indexed as

Cell LineCyclin HDatabases, FactualDeath-Associated Protein KinasesDNA RepairGene Regulatory NetworksHumansImidazolesPharmaceutical PreparationsProtein Kinase InhibitorsProteinsProtein Serine-Threonine KinasesTriazinesCyclin HDAPK3 protein, humanDeath-Associated Protein KinasesImidazolesOSI 027Pharmaceutical PreparationsProtein Kinase InhibitorsProteinsProtein Serine-Threonine KinasesSTK33 protein, humanTriazinesBiochemical pathwaysCTRPDrug developmentEDDYGene regulatory networksPrecision medicine

Identifiers

PMID28617226
PMCPMC5471944
OpenAlexW2617393191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.